Syros Pharmaceuticals, Inc.

Thank you.

Good morning and welcome to Cyrus Pharmaceutical's second quarter 2024 financial results conference call. At this time, all participants are in listen-only mode. This call is being webcast live on the Investors and Media section of Cyrus' website at www.cyrus.com. Please be advised that today's call is being recorded. At this time, I would like to turn the call over to Karin Hannedy, Director of Investor Relations and Corporate Communications at Ciros. Please go ahead.

Thank you. This morning, we issued a press release announcing our second quarter 2024 financial results. The full release is available on the section of Ciros' website at www.ciros.com. We will begin the call with prepared remarks by Conley Chee, our Chief Executive Officer, Dr. David Ross, our Chief Medical Officer, and Jason Haas, our Chief Financial Officer. We will then open the call for questions. Kristen Stevens, our Chief Development Officer, is also here on the call with us and will be available for Q&A. Before we begin, I would like to remind everyone that the statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factors section of our quarterly report on Form 10Q that we filed this morning, our annual report on Form 10K that we filed earlier in the year, and any other filings that we may make with the SEC in the future. Any forward-looking statements represent our views only as of today, and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. I would now like to turn the call over to Conley. Conley?